MAIA Biotechnology Inc (MAIA)
3.28
+0.16
(+5.13%)
USD |
NYAM |
May 17, 16:00
3.28
0.00 (0.00%)
After-Hours: 20:00
MAIA Biotechnology Cash from Financing (TTM): 13.99M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 13.99M |
December 31, 2023 | 9.271M |
September 30, 2023 | 4.053M |
June 30, 2023 | 14.19M |
March 31, 2023 | 9.946M |
Date | Value |
---|---|
December 31, 2022 | 12.48M |
September 30, 2022 | 13.90M |
June 30, 2022 | 9.123M |
March 31, 2022 | 14.14M |
December 31, 2021 | 14.03M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
4.053M
Minimum
Sep 2023
14.19M
Maximum
Jun 2023
11.51M
Average
13.19M
Median
Cash from Financing (TTM) Benchmarks
Cyclacel Pharmaceuticals Inc | 0.848M |
Avid Bioservices Inc | 8.937M |
Oragenics Inc | 0.2839M |
NeuBase Therapeutics Inc | 4.254M |
Viking Therapeutics Inc | 873.23M |